Physician
Mann, Melinda
Mann, Melinda was paid $1.08M by Medicaid between Oct 2018 and Oct 2021, across 87 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 8.6% of everything it billed.
33Billing provider infoMANN, MELINDA
BROOKLYN, NY 11230
BROOKLYN, NY 11230
33aNPI1922092444assigned 09/12/2005
33bProvider typeObstetrics & Gynecology Physician
28Total paid$1.08M
24GClaims63,268
24DCodes billed87
24AFirst – last monthOct 2018 – Oct 2021
Compared with peers
Next to other Obstetrics & Gynecology Physician providers in New York
Rank by total paid#78 of 762
Median peer was paid$22K
This provider vs. median50×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,471 | $50K | |
| 2019 | 22,766 | $444K | |
| 2020 | 18,966 | $316K | |
| 2021 | 19,065 | $269K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8.6% | 2,758 | 2,756 | $93K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8.4% | 2,746 | 2,744 | $91K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 7.3% | 1,164 | 1,160 | $79K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 4.2% | 1,364 | 1,362 | $46K |
| 87481 | 3.7% | 1,121 | 1,118 | $40K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.5% | 1,162 | 1,158 | $38K |
| 86769 | 2.9% | 1,026 | 1,014 | $31K | |
| 82607 | 2.7% | 2,065 | 2,057 | $29K | |
| 82746 | 2.7% | 2,113 | 2,105 | $29K | |
| 82728 | 2.5% | 2,144 | 2,136 | $27K | |
| 84480 | 2.5% | 2,171 | 2,161 | $27K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.1% | 863 | 862 | $23K |
75 more codes
| 87625 | 2.1% | 692 | $23K | |
| 87522 | Neg quan hep c or qual rna | 2.1% | 573 | $23K |
| 80050 | General health panel | 2.0% | 601 | $21K |
| 86376 | 1.9% | 1,521 | $20K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 255 | $20K |
| 86703 | 1.9% | 1,542 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.7% | 1,323 | $18K |
| 84432 | 1.6% | 1,172 | $18K | |
| 84144 | 1.6% | 841 | $17K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 2,220 | $16K |
| 86696 | 1.5% | 878 | $16K | |
| 84439 | 1.4% | 1,882 | $15K | |
| 82670 | 1.3% | 540 | $14K | |
| 84403 | 1.2% | 520 | $12K | |
| 86762 | 1.1% | 901 | $12K | |
| 83550 | 1.1% | 1,630 | $12K | |
| 86803 | 1.1% | 879 | $12K | |
| 86765 | 1.0% | 901 | $11K | |
| 86708 | <1% | 906 | $11K | |
| 86704 | <1% | 880 | $10K | |
| 84702 | <1% | 703 | $10K | |
| 86695 | <1% | 781 | $10K | |
| 83001 | <1% | 558 | $10K | |
| 83002 | <1% | 557 | $10K | |
| 84146 | <1% | 534 | $10K | |
| 83655 | <1% | 825 | $10K | |
| 87340 | <1% | 879 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 934 | $7K |
| 87797 | <1% | 370 | $7K | |
| 83540 | <1% | 1,111 | $7K | |
| 80053 | Comprehensive metabolic panel | <1% | 743 | $7K |
| 83625 | <1% | 810 | $7K | |
| 80061 | Lipid panel | <1% | 529 | $7K |
| 86592 | <1% | 1,551 | $6K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 150 | $6K |
| 86644 | <1% | 454 | $6K | |
| 83525 | <1% | 524 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 129 | $5K |
| 86735 | <1% | 916 | $5K | |
| 86706 | <1% | 535 | $5K | |
| 83735 | <1% | 810 | $5K | |
| 86645 | <1% | 837 | $5K | |
| 82550 | <1% | 813 | $5K | |
| 87623 | <1% | 271 | $4K | |
| 84100 | <1% | 813 | $3K | |
| 86787 | <1% | 522 | $3K | |
| 82627 | <1% | 154 | $3K | |
| 82950 | <1% | 686 | $3K | |
| 85652 | <1% | 975 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 30 | $2K |
| 82533 | <1% | 153 | $2K | |
| 76801 | <1% | 17 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 39 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 16 | $2K |
| 82947 | <1% | 584 | $2K | |
| 82977 | <1% | 256 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 14 | $1K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 15 | $1K |
| 86747 | <1% | 75 | $996.75 | |
| 84481 | <1% | 54 | $882.75 | |
| 86141 | <1% | 54 | $673.65 | |
| 84466 | <1% | 46 | $570.08 | |
| 82397 | <1% | 50 | $541.24 | |
| 87660 | <1% | 22 | $432.34 | |
| 87510 | <1% | 22 | $432.34 | |
| 87480 | <1% | 22 | $432.34 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 17 | $382.33 |
| 90656 | <1% | 13 | $325.00 | |
| 83498 | <1% | 13 | $313.06 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 107 | $240.75 |
| 86778 | <1% | 14 | $160.56 | |
| 86900 | <1% | 57 | $152.59 | |
| 86901 | <1% | 57 | $152.59 | |
| 84436 | <1% | 453 | $56.17 | |
| 84479 | <1% | 240 | $6.78 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.